Vector Science and Therapeutics Corp. PAIN
TSXV · Canada · Finance
CAD 1.99-0.04 (-1.97%)
Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Mequon, Wisconsin--(Newsfile Corp. - September 25, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors has approved the grant of 150,000 stock options (the "Options") to an Officer of the Company in accordance with the Company's stock option plan. The Options vest in 25% tranches over a three year period, have an exercise price of C$1.80 and are exercisable for a period of five years from the date of grant. This...
Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") is pleased to announce that the Company has entered into an investor relations agreement (the "IR Agreement") with RedChip Companies, Inc. ("RedChip") through its principal, Dave Gentry, dated August 24, 2026.
Vector Science & Therapeutics Corp. (TSXV: PAIN) (the "Company") today announced that the first of four planned manufacturing suites at its LyoGenesis Manufacturing facility is now producing pharma-grade peptides, putting the Company on track to begin fulfilling Vector's existing customer orders for nine peptides this month.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.